Abstract
Two women in their sixties were diagnosed with inoperable locally advanced epithelioid malignant pleural mesothelioma, c-stage IIIB. Post-chemotherapy, the tumors down-staged to yc-stage IA, and pleurectomy/decortication were performed. The pathological diagnoses were p-stages II and IA. One patient had tumor recurrence 6 months after surgery; she is currently undergoing fourth-line chemotherapy and is alive 30 months postoperatively. The second patient had tumor recurrence 4 months after surgery and died 2 months later. Conversion surgery for advanced malignant mesothelioma does not improve progression-free survival but might have a chance to extend overall survival in selected patients without deteriorating performance status.
Similar content being viewed by others
References
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN guidelines insights malignant pleural mesothelioma version 3. J Natl Compr Cance Netw. 2016;14:36–825.
Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–5.
Bolukbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7:900–5.
Nakas A, von Meyenfeldt E, Lau K, Muller S, Waller D. Long-term survival after lung-sparing total pleurectomy for locally advanced (international mesothelioma interest group stage T3–T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2012;41:1031–6.
Friedberg JS, Simone CB 2nd, Culligan MJ, Barsky AR, Doucette A, McNulty S, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103:912–9.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.
Goto Y, Okada M, Kijima T, Denham C, Kaukel E, Ruffie P. A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT). J Thorac Oncol. 2017;12:1883.
Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75:360–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed consent
Informed consent was obtained from both the patients.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Terada, Y., Isaka, M., Murakami, H. et al. Conversion surgery for locally advanced malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 68, 1547–1550 (2020). https://doi.org/10.1007/s11748-020-01329-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-020-01329-y